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Abstract Utrophin is a large cytoskeletal protein which shows 
high homology to dystrophin. In contrast to the sarcolemmal 
distribution of dystrophin, utrophin accumulates at the postsynap- 
tic membrane of the neuromuscular junction. Because of its local- 
ization within this compartment of muscle fibers, expression of 
utrophin may be significantly influenced by the presence of the 
motor nerve. We tested this hypothesis by denervating muscles 
of mdx mouse and monitoring levels of utrophin and its mRNA 
by immunofluorescence, immunobiotting and RT-PCR. A sig- 
nificant increase in the number of utrophin positive fibers was 
observed by immunofluorescence 3 to 21 days after sectioning of 
the sciatic nerve. Quantitative analyses of utrophin and its tran- 
scripts in hindlimb muscles denervated for two weeks showed only 
a moderate increase in the levels of both utrophin (~ 2-fold) and its 
transcript (-60 to 90%). The present data suggest hat although 
utrophin is a component of the postsynaptic membrane, its neural 
regulation is distinct from that of the acetylcholine receptor. 
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1. Introduction 
The most severe and prevalent primary myopathy is the 
Duchenne form of muscular dystrophy (DMD) [1]. The genetic 
defect responsible for this disease is located on the short arm 
of the X chromosome and prevents the production of normal 
size dystrophin, a large cytoskeletal protein of 427 kDa (for 
review see refs. [2,3]). In 1989, Love et al. [4] showed the ex- 
istence of an autosomal homologue to dystrophin subsequently 
named utrophin since it is expressed in a variety of tissues ([5,6], 
and see for review [7]). Further studies revealed that this gene 
encodes a large cytoskeletal protein highly homologous to 
dystrophin in its C-terminus [8] and that it presents a genomic 
organization similar to the structure of the dystrophin gene 
[9,10]. The utrophin gene is located on chromosome 6 in human 
and 10 in mouse [4,11]. 
In contrast to dystrophin which is found on the cytoplasmic 
face of the sarcolemma in normal muscles [12,13,14], utrophin 
accumulates specifically at the levels of the neuromuscular syn- 
apse and myotendinous junction in both normal nd dystrophic 
adult muscles [15-24]. Additional studies have shown that utro- 
phin is present in greater amounts in small caliber muscle fibers 
of mdx mice [18,25], small or regenerating muscle fibers of 
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DMD patients [19,26-29] as well as in embryonic and neo-natal 
muscles ([5,18,19,22,30,31], see also [27]). Recently, it was also 
reported that some muscles of mdx mice may contain signifi- 
cantly more utrophin in comparison to normal mouse muscles 
[321. 
Although the distribution of utrophin in normal and dys- 
trophic muscles appears well established, little is known con- 
cerning the cellular and molecular mechanisms involved in its 
regulation. Given the co-distribution of utrophin with the ace- 
tylcholine receptor (AChR) at the neuromuscular junction and 
the well-documented increase in AChR expression in dener- 
vated muscles [33-35], it may be hypothesized that expression 
of utrophin is significantly influenced by the presence of the 
motor nerve. A first indication that this may be the case was 
provided by Takemitsu et al. [I 8] who showed that denervation 
of mdx mouse muscle appears to increase xpression of utro- 
phin to a level similar to that observed in embryonic muscle 
fibers. However, in the latter study, the impact of muscle den- 
ervation was judged strictly by immunofluorescence experi- 
ments for which no quantitative stimates of the extent of 
reexpression was provided. Therefore, the purpose of the pres- 
ent study was to examine the expression of utrophin in dener- 
vated mdx mouse muscles by immunofluorescence and to quan- 
tify the impact of denervation by immunoblot analysis. In addi- 
tion, we wished to gain insight into the mechanisms underlying 
the denervation-associated increase in utrophin expression by 
quantifying levels of mRNA encoding utrophin in denervated 
muscles. 
2. Materials and methods 
2.1. Antibodies 
Rabbit anti-Torpedo dystrophin was produced in our laboratory 
(Cartaud et al., 1992). The rabbit anti-utrophin a tibody was a kind gift 
of Dr. T. Khurana, Harvard University [5]. 
2.2. Denervation 
Ten-week-old mdx mice were anesthetized with chloral hydrate 
(3.5%, 3 ml/kg of body weight, i.p.) or sodium pentobarbital (35 mg/kg 
of body weight, i.p.). An incision was made at the mid-thigh region a d 
the sciatic nerve exposed by blunt dissection of the underlying muscula- 
ture. A mid-point axotomy was made and a ~ 1 cm segment of the nerve 
was removed toprevent reinnervation. At varying time-points thereaf- 
ter (1, 3, 5, 7, 14, 30, 45, 60 and 90 days), animals were euthanized, and 
both denervated and contralateral gastrocnemius muscles were re- 
moved. Muscles were snap frozen in melting isopentane pre-cooled with 
liquid nitrogen. Samples were kept at -80°C until used. 
2.3. Immunocytochemistry 
Antibodies to dystrophin (1/100) and utrophin (1/1000) were diluted 
in phosphate-buffered saline (PBS) containing 3% bovine serum albu- 
min (BSA). These antibodies were applied onto separate serial cross- 
0014-5793195/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)01131-5 
394 B.J. Jasmin et al./FEBS Letters 374 (1995) 393-398 
B.J. Jasmin et al./FEBS Letters 374 (1995) 393-398 395 
D C D C D C T 
~7d"~ ~'14d.-~ ~-14d"~ 
Fig. 2. Immunoblot analysis of utrophin levels in control and dener- 
vated hindlimb muscles of rndx mice. Utrophin was detected by chem- 
iluminescence following incubation of the upper part of the im- 
munoblot which corresponds to high molecular weight proteins (> 200 
kDa), with anti-utrophin antibodies. The bottom panel corresponds to
Ponceau red staining of proteins in the lower part of the blot and shows 
that similar amounts of proteins were loaded in each pair of well. Each 
pair of lanes represents denervated (D) and contralateral control (C) 
limb muscles obtained 7 or 14 days after nerve sectioning. The arrow 
indicates the position of dystrophin (~400 kDa) from Torpedo electric 
tissue (lane T) which ran together with the muscle samples on the gel. 
As shown, denervated muscles displayed a noticeable increase in the 
levels of utrophin as compared to control muscles. 
sections (10/~m). After I h of incubation, sections were rinsed with PBS 
containing 0.1% Tween. This was then followed by an additional 1 h 
incubation with a fluorescein isothiocyanate (FITC)-conjugated goat 
anti-rabbit IgG diluted (1/100) in PBS with 3% BSA. Sections were 
thoroughly rinsed with PBS, mounted in moviol and examined by 
epifluorescence using a Leitz photomicroscope. 
2.4. Gel electrophoresis and immunoblotting 
SDS/PAGE of proteins from denervated and contralateral control 
muscles was carried out as described [36] with the following modifica- 
tions. Equivalent amount of control and 7 or 14 day-denervated mus- 
cles representing approximately 1.2 mg of total proteins, was homoge- 
nized in 300/.tl of Tris buffer (100 mM; pH 6.9) containing 25% glycerol, 
13% SDS, 1 mM EDTA, 1 mM benzamidine and 1 mM PMSF. Protein 
concentrations were determined according to the bicinchoninic acid 
(BCA) Protein Assay Reagent protocol (Pierce Laboratories). For gel 
electrophoresis, samples were heated to 60°C for 10 min. Following the 
addition of bromophenol b ue and mercaptoethanol (5%), a total of 140 
pg of whole muscle proteins were loaded in each well. Samples were 
separated by one dimensional SDS/6% PAGE using the Mini Protean 
II slab gel system (BioRad). 
lmmunoblot analysis of utrophin was performed after transfer onto 
nitrocellulose [37]. Detection of utrophin was performed via enhanced 
chemiluminescence reaction (ECL detection kit, Amersham). The 
upper part of the nitrocellulose filter was incubated with the antibody 
against utrophin (1/2000), and a goat horseradish peroxidase-conju- 
gated anti-rabbit lgG was used as a secondary antibody. The lower part 
of the same blot was stained with Ponceau red to show that equivalent 
amount of proteins was loaded for each sample. The luminescent signal 
on the XR film was scanned and quantified using the NIH image 
program. 
2.5. RNA extraction and quantitative RT-PCR 
For these studies, tibialis anterior and extensor digitorum longus 
muscles (TA/EDL) as well as triceps surae and plantaris muscles (TS/ 
PL) were excised and rapidly frozen in liquid nitrogen. Total RNA was 
extracted using the acid guanidinium phenol chloroform procedure 
[38]. Both TA/EDL and TS/PL muscle groups were homogenized using 
a Polytron in 10 volumes of solution D. Following the last precipitation, 
the RNA was washed with 75% ethanol and stored at -20 ° C. 
RNA pellets from control and denervated muscles were dissolved in 
50/zl of RNase-free water. From each stock RNA sample, 10/11 was 
further diluted 100-fold and only 2/zl of this dilution was used for 
reverse transcription and amplification with the polymerase chain reac- 
tion (RT-PCR) as described in detail elsewhere [39,40]. Briefly, a master 
reverse transcription mixture was prepared containing 5 mM MgCI2, 
Ix PCR buffer 1I (50 mM KCI, 10 mM Tris-HCl (pH 8.3)), 1 mM 
dNTPs, 20 U RNase inhibitor, 50 U reverse transcriptase, and 2.5 mM 
of random hexamers (GeneAmp RNA PCR kit; Perkin Elmer Cetus). 
The master mix was aliquoted and the RNA subsequently added. Neg- 
ative controls consisted of reverse transcription mixtures in which total 
RNA was replaced with RNase-free water. Reverse transcription was 
performed for 45 min at 42°C and heated to 99°C for 5 min to terminate 
the reaction. 
A PCR master mix was then prepared with final concentrations 
of 2.5 U AmpliTaq DNA polymerase, 2 mM MgC12 and 1 × PCR buffer 
II. Utrophin cDNAs were specifically amplified using primers designed 
on the basis of the mouse utrophin sequence. The 5' (5', 3': 
GGGGAAGATGTGAGAGATTT) and 3' (5', 3': GTGTGGTGAG- 
GAGATACGAT) primers amplify a 548 bp target sequence. PCR was 
performed in a DNA thermal cycler (Perkin Elmer) by adding 5/11 of 
the reverse transcription mixture to 20/~1 of the PCR master mix. Each 
cycle consisted of denaturation at94°C for 1 min, primer annealing at 
65°C for 1 min and extension at 72°C for 1 min. A final 10 min 
elongation step at 72°C was added after the last cycle. Typically, ampli- 
fication was performed for 32 cycles for TA/EDL and TS/PL muscles 
since our experiments showed that under these reaction conditions, 
amplification was within the linear range (see also refs. [39,40]). PCR 
products were visualized on a 1.5% agarose gel containing ethidium 
bromide. The 100 bp molecular weight marker (Gibco BRL) was used 
to estimate the molecular weight of the PCR products. Quantitative 
PCR experiments under non-competitive conditions were performed as 
described [39,40] since in the present s udies, we were primarily inter- 
ested in comparing the relative abundance of utrophin mRNAs in 
control and enervated muscles. For these, 2 × 106 cpm of 32p-end 
labelled primers were added to the PCR reaction mixture. After ampli- 
fication, 10/zl aliquots of the PCR reactions were Cerenkov counted 
and separated by gel electrophoresis on 1.5% agarose gels. The gels 
were then photographed, the appropriate gel bands excised and the 
amount of radioactivity determined by Cerenkov counting. The counts 
per minute were adjusted for the amount of sample loaded per gel lane 
and background activity. These final counts per minute are propor- 
tional to the relative abundance of utrophin transcripts per muscle 
groups. 
3. Results 
In a first series of experiments, we examined the distr ibution 
of utrophin in cryostat sections of control muscles obtained 
or-- 
Fig. 1. Immunofluorescence detection of dystrophin and utrophin in cryostat sections of control and denervated hindlimb muscles of 10-week-old 
mdx mouse. A and B represent immunolabelling of dystrophin and utrophin in control skeletal muscles, respectively. Note that in A, only a few 
revertant fibers were stained (arrow). In B, intensive immunostaining of nerves (N), blood vessels (BV) and neuromuscular junctions (arrows) was 
observed. Also, a heterogeneous staining pattern was seen at the periphery of myofibers. C and D show immunolabelling of utrophin in 3- and 14-day 
denervated muscles, respectively. As shown, denervation i duces an increase in the number of utrophin-positive fibers at day 3 (C). A further increase 
was seen at day 14 (D). 
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Fig. 3. Effects of denervation on expression of utrophin transcripts in 
mdx mouse muscles. Shown are representative examples of thidium 
bromide stained agarose gels of utrophin PCR products for denervated 
(D) and control (C) anterior (TA-EDL) and posterior (TS-PL) crural 
muscle groups of mdx mice. Negative control ane is marked with a 
minus. 
from mdx mice. Transverse tissue sections were immunola- 
belled with either anti-dystrophin or anti-utrophin antibodies. 
Immunolabelling of mdx hindlimb muscles with anti-dystro- 
phin antibodies showed that only a few revertant muscle fibers 
were decorated (arrow) thereby confirming the absence of this 
protein from the majority of muscle fibers (Fig. 1A). Anti- 
utrophin antibodies r vealed in addition to labelling of neu- 
romuscular (arrows) and myotendinous j nctions (not shown), 
a heterogeneous pattern of immunostaining (Fig. 1B). Only a 
few fibers, presumably regenerating myofibers either isolated 
or grouped, showed utrophin immunoreactivity at the sar- 
colemma. A strong immunoreactivity was also observed in 
nerve trunks and blood vessels (arrow). 
In denervated hindlimb uscles of mdx mice, anti-dystro- 
phin antibodies howed the same pattern of labelling as that 
observed in control muscles (not shown). Using anti-utrophin 
antibodies, however, we observed a significant increase in the 
number of utrophin-positive fibers as early as 3 days after 
denervation (Fig. 1C). A steady increase of the number of 
utrophinpositive fibers was observed at later time-points and 
reached a plateau between 14 to 21 days following nerve 
transection (Fig. 1D). The number of utrophin-positive fibers 
remained elevated until the end of the third month after dener- 
vation. 
In a series of complementary experiments, we quantitated the 
magnitude of this increase by comparing levels of utrophin 
expression i control and enervated muscles of mdx mice with 
immunoblotting assays. For these experiments, an equal 
amount of protein was loaded in each pair of well as evidenced 
by Ponceau red staining of the lower part of the blot (Fig. 2). 
Using the utrophin antibody, we detected the presence of a 
band of ~420 kDa in both control and enervated muscles, 
Densitometric analysis of the blots revealed a significant in- 
crease (-2- to 3-fold) in utrophin levels 14 days following sec- 
tioning of the sciatic nerve (Fig. 2). 
To determine the influence of the motor nerve on expression 
of the utrophin gene, we xamined in a separate set of experi- 
ments, levels of utrophin mRNAs in control and denervated 
muscles of rndx mice. For these studies, the relative abundance 
of utrophin transcripts was measured by quantitative RT-PCR 
in both anterior (TA-EDL) and posterior (TS-PL) crural mus- 
cle groups of mdx mice following 2 weeks of denervation (Fig. 
3). The identity of the utrophin PCR product (548 bp) was 
confirmed by restriction enzyme mapping and predicted size 
based upon the sequence of a partial cDNA clone (not shown). 
As illustrated in Fig. 4, denervation increased expression of 
utrophin transcripts by approximately 62% and 93% in anterior 
and posterior crural muscle groups, respectively. 
4. Discussion 
The aims of the present study were two fold. First, we quan- 
titated the extent of utrophin re-expression i  denervated mdx 
mouse hindlimb muscles. Second, we wished to gain sights 
into the mechanisms underlying the denervation-associated in- 
crease in utrophin expression. Our results show that, despite a
noticeable increase in the number of utrophin positive fibers as 
observed by immunofluorescence, utrophin levels are moder- 
ately increased by two weeks of denervation as revealed by 
densitometric analysis of immunoblots. Furthermore, quantita- 
tive RTPCR experiments showed that this increase in protein 
levels is sustained by a parallel increase in the abundance of 
utrophin mRNAs thereby indicating the involvement of pre- 
translational regulatory mechanisms in utrophin re-expression. 
During myo- and synaptogenesis, expression of utrophin ap- 
pears modulated such that increased levels of expression have 
been reported in both embryonic and neo-natal muscles 
[5,18,19,22,27,30,31]. In mdx mouse muscles, levels of utrophin 
decrease progressively reaching minimal levels three to four 
weeks after birth [31]. Although the developmental regulation 
of utrophin appears well established, the influence that the 
nerve may exert on utrophin is unclear. To date, this issue has 
only been addressed using the denervation model. For instance, 
in muscles of normal mice, denervation leads to no [16] or 
modest [18] changes in utrophin expression and localization. By 
contrast, denervation of mdx mouse muscle has been reported 
to have a pronounced effect on utrophin expression. Indeed, 
Takemitsu and colleagues [18] have shown on the basis of 
immunofluorescence experiments, re-expression of utrophin in 
denervated muscles that appeared to reach levels as high as 
those observed in embryonic muscle fibers. Our quantitative 
estimates based on densitometric analysis of immunoblots do 
not support hese findings. In fact, our results indicate that the 
denervation-associated increase in utrophin expression is con- 
siderably less than assumed from immunofluorescence experi- 
ments reaching only moderate levels. This is further supported 
14000111 C T' 14000 ~1 ~ CTL 
D DEN 12000 12000 
10000 10000 
8000 8000 
0ooo i 0ooo 
i 
"~ 4000 I 4000 
- 1 • -. 2ooo! 2ooo 
O- -  0 
TA - EDL TS-  PL 
Fig. 4. Quantitation of utrophin mRNA levels in control and ener- 
vated hindlimb muscles of mdx mice. Utrophin mRNA expression was 
significantly increased in both the anterior (TA-EDL) and posterior 
(TS-PL) crural muscle groups ofmdx mice following 2 weeks of dener- 
vation. Shown are the results of quantitative RT-PCR experiments 
performed on 3 control and 3 denervated mice. Values are mean + S.D. 
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by analysis of mRNA levels which in agreement with the im- 
munoblot data shows a modest increase in utrophin transcripts. 
The apparent discrepancy may be reconciled if we consider the 
methods used to determine the impact of denervation on utro- 
phin expression. In Takemitsu et al. [18], this was trictly done 
by immunofluorescence. Using this method, we similarly ob- 
served a rather strong re-expression of utrophin in numerous 
fibers of denervated muscles. However, the apparent increase 
of fluorescent fibers is difficult to quantify. Also, cross-reactiv- 
ity of the anti-utrophin antibody with other membrane compo- 
nents is likely as seen in immunoblotting experiments. This fact 
should be taken into consideration when making a direct com- 
parison between immunofluorescence observations and bio- 
chemical estimates of the protein or mRNA increases. 
The impact of denervation on expression of AChR in mus- 
cles has been extensively studied and it is now well established 
that denervation leads to pronounced increases in the levels of 
AChR, The increases vary between five to 100 fold according 
to the species, muscle and time-point studied (see for review 
[33]). This increase in AChR expression i  denervated muscles 
reflects de novo synthesis as exemplified by the large increases 
in levels of mRNAs encoding the various AChR subunits 
[34,35]. In this context, it has been suggested that utrophin 
expression in denervated muscles increases significantly [18] 
yet, our quantitative analyses clearly indicate that it is not the 
case. Thus, although utrophin is a synaptic omponent which 
may be involved in the organization of the postsynaptic mem- 
brane domain of the neuromuscular junction [41-43], its regula- 
tion is clearly distinct from that of AChR. 
The 43 kDa protein is another important constituent of the 
postsynaptic membrane of the neuromuscular junction [44,45]. 
In both Torpedo electrocyte and differentiated mouse skeletal 
muscle, the AChR and 43 kDa protein are present in nearly 
equimolar amounts [46]. Because of its localization and inti- 
mate relationship with AChR, it has been also hypothesized 
that expression of this protein may be markedly influenced by 
the presence of the motor nerve. In separate xperiments, how- 
ever, Frail et al. [47] and Froehner [48] showed that denervation 
of rodent muscle resulted only in marginal increases in the 
expression of mRNA encoding the 43 kDa protein. These re- 
sults obtained with a distinct cytoskeletal protein of the 
postsynaptic membrane are thus coherent with our observa- 
tions. Taken together, these findings indicate that in striking 
contrast o the pronounced effect that innervation has on the 
expression of AChR, synapse-specific cytoskeletal proteins are 
only marginally influenced by denervation. 
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